Substance Use Disorder Market Size, Epidemiology, Trends, and Forecast 2025-2035

The 7 major substance use disorder markets reached a value of USD 5.3 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 7.7 Million by 2035, exhibiting a growth rate (CAGR) of 3.51% during 2025-2035.

The matter of substance use disorder (SUD) in connection with respiratory health has drawn attention with the increasing rate of smoking, vaping, and opioid abuse with lung-related problems. The SUD respiratory market works on the treatment of chronic obstructive pulmonary disease (COPD), residual lung damage due to chronic smoking, and opioid-induced respiratory depression. As the year 2025 approaches, the management of patients suffering from addiction-related respiratory problems is changing with the development of new therapies, digital health solutions, and harm-reduction approaches.



The Relationship of Substance Use with Respiratory Health

The use of tobacco, cannabis, and opiate drugs, and other illicit drugs are associated with considerable impact on lung function. The two major contributing factors of COPD, emphysema, lung cancer, and opioids suppress breathing which increases chances for fatal overdose. Use of methamphetamines and crack-cocaine result in pulmonary hypertension and chronic bronchitis. These factors alongside the need to treat the addiction calls for an adequate system based on a multidisciplinary approach for respiratory care.

SUD Respiratory Market Outlook 2025

  1. Therapeutic Strategies for Opioid Addiction and Breathing

The use of the internet and mobile devices in the treatment of SUD and respiratory illnesses is increasing. Breathing and monitoring systems such as telehealth AI are evaluating the overdosing potential of opioid users by measuring their breathing patterns. Alongside these systems, counselors provide remote consultations aimed at smoking cessation. Opioid use disorder (OUD) is treated using PDTs such as reSET which is from prescription digital therapeutics. This device is now being fused with other respiratory monitoring systems for better patient care.

  1. New Treatment Approaches for Smoking and Opioid Cessation

Cytisinicline, a novel plant-derived medication aimed at assisting smoking cessation, is offering better recovery results alongside extended-release formulations of naloxone. Anti-inflammatory agents are also being identified for the restoration of lung tissues that are damaged due to the use of smoke and vapor.  

  1. Innovations In Reducing Harm
  1. Personalized Medicine and Biomarker Research

New diagnostics genomics is stratifying patients according to the likelihood of experiencing severe lung injury from chronic abusive behaviors. Poisonous biomarker treatments like smoking-related lung disease targeted anti-fibrotic therapy are being put through clinical testing.  

  1. Wearable Respiratory Monitors  

Smart wearable technology that tracks coughing, blood oxygen saturation, and respiratory rate is crucial for initiating timely interventions in SUD patients. Such devices notify providers of potential relapse or deterioration in lung function.  

Market Growth and Future Outlook  

With rising addiction prevalence and increased funding toward harm reduction, the SUD respiratory market is poised for substantial growth by 2025. North America leads the market due to high opioid and vaping-related prescription cases, while Europe and Asia-Pacific are adopting overdose rescue and smoking cessation programs.

Request for a sample of this report: https://www.imarcgroup.com/substance-use-disorder-market/requestsample

Countries Covered:

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country:

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the substance use disorder market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the substance use disorder market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

This report also provides a detailed analysis of the current substance use disorder market drugs and late-stage pipeline drugs.

In-Market Drugs:

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

  • Drug overview
  • Mechanism of action
  • Regulatory status
  • Clinical trial results
  • Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the substance use disorder market has been studied in the report with the detailed profiles of the key players operating in the market.

Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/request?type=report&id=6917&flag=A

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

Comments

Post a Comment

Popular posts from this blog

Cancer Pain Market Size, Epidemiology, Trends, and Forecast 2025

Image
  The   cancer pain market size   reached a value of USD 1,778.2 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 2,625.8 Million by 2035, exhibiting a growth rate (CAGR) of 3.61% during 2025-2035. The year of 2025 may see the cancer pain market in a raging state, made dynamic from the rise in cancer cases, changing treatment strategies, and significant technological progress. Cancer pain afflicts approximately 53% of all individuals diagnosed with the disease and 64% of those who have the illness at the advanced stage, holding a central position in oncology care. With increasing global cancer incidence, the demand for effective and patient-friendly management of pain has never been higher. A major factor responsible for this expansion is the rising prevalence of cancer worldwide. As the population ages and lifestyle-related risk factors increase, more and more people are getting d...
Read more

Obstructive Sleep Apnea Market Size, Epidemiology, Trends, and Forecast

Image
The 7 major  obstructive sleep apnea markets size  reached a value of USD 794.9 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 4,066.7 Million by 2035, exhibiting a growth rate (CAGR) of 16.2% during 2025-2035. Increased global awareness, increasing incidence rates, and technological advancements are largely contributing to the growth of the OSA market in 2025. Sleep apnea refers to periodic arousals from sleep accompanied by cessation of breathing and is a common ailment affecting millions of people across the globe. With increasing awareness about associated health risks such as hypertension, cardiovascular diseases, and diabetes, the demand for diagnosis and treatment on time is rapidly increasing.  One of the leading causes of market growth is the increasing incidences of sleep apnea. In the name of modern lifestyles, with instances of poor sleep hygiene, sedentary behavior, and increased calorie intake, sleep apnea cases are surging a...
Read more

Inflammatory Bowel Disease Market Overview and Trends in 2025

Image
 The 7 major  inflammatory bowel disease markets  reached a value of USD 14.92 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 20.08 Billion by 2035, exhibiting a growth rate (CAGR) of 2.73% during 2025-2035. Demand surges in the IBD market as the worldwide burden of chronic gastrointestinal disorders continues to increase in 2025. Crohn’s disease and ulcerative colitis are the two most common types of IBD;  they are lifelong diseases characterized by inflammation of the gastrointestinal tract. Increased awareness of the diseases coupled with the development of diagnostic and therapeutic measures is accelerating market growth globally. The focus areas of the market in 2025 are associated with the growing burden of IBD, particularly in developed North American and European countries. But there is a notable increase in prevalence in portions of Asia and even some Latin American countries, which is likely a result of urban lifestyle, dietary h...
Read more